Top

Published in:

Open Access 01-12-2023 | Alzheimer's Disease | Research

Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer’s disease

Authors: Tahir Ali, Antonia N. Klein, Keegan McDonald, Lovisa Johansson, Priyanka Ganguli Mukherjee, Martin Hallbeck, Katsumi Doh-ura, Hermann M. Schatzl, Sabine Gilch

Published in: Journal of Neuroinflammation | Issue 1/2023

Abstract

Alzheimer’s disease (AD) is an incurable, progressive and devastating neurodegenerative disease. Pathogenesis of AD is associated with the aggregation and accumulation of amyloid beta (Aβ), a major neurotoxic mediator that triggers neuroinflammation and memory impairment. Recently, we found that cellulose ether compounds (CEs) have beneficial effects against prion diseases by inhibiting protein misfolding and replication of prions, which share their replication mechanism with Aβ. CEs are FDA-approved safe additives in foods and pharmaceuticals. Herein, for the first time we determined the therapeutic effects of the representative CE (TC-5RW) in AD using in vitro and in vivo models. Our in vitro studies showed that TC-5RW inhibits Aβ aggregation, as well as neurotoxicity and immunoreactivity in Aβ-exposed human and murine neuroblastoma cells. In in vivo studies, for the first time we observed that single and weekly TC-5RW administration, respectively, improved memory functions of transgenic 5XFAD mouse model of AD. We further demonstrate that TC-5RW treatment of 5XFAD mice significantly inhibited Aβ oligomer and plaque burden and its associated neuroinflammation via regulating astrogliosis, microgliosis and proinflammatory mediator glial maturation factor beta (GMFβ). Additionally, we determined that TC-5RW reduced lipopolysaccharide-induced activated gliosis and GMFβ in vitro. In conclusion, our results demonstrate that CEs have therapeutic effects against Aβ pathologies and cognitive impairments, and direct, potent anti-inflammatory activity to rescue neuroinflammation. Therefore, these FDA-approved compounds are effective candidates for developing therapeutics for AD and related neurodegenerative diseases associated with protein misfolding.

Available only for authorised users

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5. https://doi.org/10.1126/science.1566067.CrossRefPubMed

Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329–44. https://doi.org/10.1056/NEJMra0909142.CrossRefPubMed

Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17. https://doi.org/10.1016/S0140-6736(15)01124-1.CrossRefPubMed

Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59–70. https://doi.org/10.1111/ene.13439.CrossRefPubMed

Rosenberg RN, Lambracht-Washington D, Yu G, et al. Genomics of Alzheimer disease. JAMA Neurol. 2016;73(7):867–74. https://doi.org/10.1001/jamaneurol.2016.0301.CrossRefPubMedPubMedCentral

Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300(5618):486–9. https://doi.org/10.1126/science.1079469.CrossRefPubMed

Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120(4):545–55. https://doi.org/10.1016/j.cell.2005.02.008.CrossRefPubMed

Walsh DM, Selkoe DJ. A beta oligomer—a decade of discovery. J Neurochem. 2007;101(5):1172–84. https://doi.org/10.1111/j.1471-4159.2006.04426.x.CrossRefPubMed

Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837–42. https://doi.org/10.1038/nm1782.CrossRefPubMedPubMedCentral

10.

Minter MR, Main BS, Brody KM, et al. Soluble amyloid triggers a myeloid differentiation factor 88 and interferon regulatory factor 7 dependent neuronal type-1 interferon response in vitro. J Neuroinflammation. 2015;12:71. https://doi.org/10.1186/s12974-015-0263-2.CrossRefPubMedPubMedCentral

11.

Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777–83.CrossRefPubMed

12.

Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets. 2009;8(1):7–15. https://doi.org/10.2174/187152709787601821.CrossRefPubMed

13.

Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):383–421. https://doi.org/10.1016/s0197-4580(00)00124-x.CrossRefPubMedPubMedCentral

14.

Tobinick E, Gross H, Weinberger A, et al. TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Med Gen Med. 2006;8(2):25.

15.

Alvarez A, Cacabelos R, Sanpedro C, et al. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging. 2007;28(4):533–6. https://doi.org/10.1016/j.neurobiolaging.2006.02.012.CrossRefPubMed

16.

Dressman JB, Adair CH, Barnett JL, et al. High-molecular-weight hydroxypropylmethylcellulose. A cholesterol-lowering agent. Arch Intern Med. 1993;153(11):1345–53.CrossRefPubMed

17.

Maki KC, Davidson MH, Torri S, et al. High-molecular-weight hydroxypropyl methylcellulose taken with or between meals is hypocholesterolemic in adult men. J Nutr. 2000;130(7):1705–10. https://doi.org/10.1093/jn/130.7.1705.CrossRefPubMed

18.

Maki KC, Carson ML, Miller MP, et al. Hydroxypropyl methylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia. Eur J Clin Nutr. 2009;63(8):1001–7. https://doi.org/10.1038/ejcn.2009.9.CrossRefPubMed

19.

Reppas C, Swidan SZ, Tobey SW, et al. Hydroxypropylmethylcellulose significantly lowers blood cholesterol in mildly hypercholesterolemic human subjects. Eur J Clin Nutr. 2009;63(1):71–7. https://doi.org/10.1038/sj.ejcn.1602903.CrossRefPubMed

20.

Bartley GE, Yokoyama W, Young SA, et al. Hypocholesterolemic effects of hydroxypropyl methylcellulose are mediated by altered gene expression in hepatic bile and cholesterol pathways of male hamsters. J Nutr. 2010;140(7):1255–60. https://doi.org/10.3945/jn.109.118349.CrossRefPubMed

21.

Hung SC, Anderson WH, Albers DR, et al. Effect of hydroxypropyl methylcellulose on obesity and glucose metabolism in a diet-induced obesity mouse model. J Diabetes. 2011;3(2):158–67. https://doi.org/10.1111/j.1753-0407.2011.00118.x.CrossRefPubMed

22.

Kim H, Bartley GE, Young SA, et al. HPMC supplementation reduces abdominal fat content, intestinal permeability, inflammation, and insulin resistance in diet-induced obese mice. Mol Nutr Food Res. 2012;56(9):1464–76. https://doi.org/10.1002/mnfr.201200082.CrossRefPubMed

23.

Kim H, Turowski M, Anderson WH, et al. Supplementation of hydroxypropyl methylcellulose into yeast leavened all-whole grain barley bread potentiates cholesterol-lowering effect. J Agric Food Chem. 2011;59(14):7672–8. https://doi.org/10.1021/jf104821b.CrossRefPubMed

24.

Ban SJ, Rico CW, Um IC, et al. Antihyperglycemic and antioxidative effects of hydroxyethyl methylcellulose (HEMC) and hydroxypropyl methylcellulose (HPMC) in mice fed with a high fat diet. Int J Mol Sci. 2012;13(3):3738–50. https://doi.org/10.3390/ijms13033738.CrossRefPubMedPubMedCentral

25.

Brockman DA, Chen X, Gallaher DD. Hydroxypropyl methylcellulose, a viscous soluble fiber, reduces insulin resistance and decreases fatty liver in Zucker Diabetic Fatty rats. Nutr Metab (Lond). 2012;9(1):100. https://doi.org/10.1186/1743-7075-9-100.CrossRefPubMed

26.

Wang Y, Harding SV, Eck P, et al. High-molecular-weight β-glucan decreases serum cholesterol differentially based on the CYP7A1 rs3808607 polymorphism in mildly hypercholesterolemic adults. J Nutr. 2016;146(4):720–7. https://doi.org/10.3945/jn.115.223206.CrossRefPubMed

27.

Burdock GA. Safety assessment of hydroxypropyl methylcellulose as a food ingredient. Food Chem Toxicol. 2007;45:2341–51. https://doi.org/10.1016/j.fct.2007.07.011.CrossRefPubMed

28.

Drozen MS. GRAS notification for hydroxypropyl methylcellulose; https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm269093.pdf.

29.

Arca HC, Mosquera-Giraldo LI, Bi V, et al. Pharmaceutical applications of cellulose ethers and cellulose ether esters. Biomacromol. 2018;19(7):2351–76. https://doi.org/10.1021/acs.biomac.8b00517.CrossRef

30.

Teruya K, Oguma A, Nishizawa K, et al. Pyrene conjugation and spectroscopic analysis of hydroxypropyl methylcellulose compounds successfully demonstrated a local dielectric difference associated with in vivo anti-prion activity. PLoS ONE. 2017;12(9):e0185357. https://doi.org/10.1371/journal.pone.0185357.CrossRefPubMedPubMedCentral

31.

Teruya K, Oguma A, Nishizawa K, et al. A single subcutaneous injection of cellulose ethers administered long before infection confers sustained protection against prion diseases in rodents. PLoS Pathog. 2016;12(12):e1006045. https://doi.org/10.1371/journal.ppat.1006045.CrossRefPubMedPubMedCentral

32.

Abdulrahman BA, Tahir W, Doh-Ura K, et al. Combining autophagy stimulators and cellulose ethers for therapy against prion disease. Prion. 2019;13(1):185–96. https://doi.org/10.1080/19336896.2019.1670928.CrossRefPubMedPubMedCentral

33.

Hannaoui S, Arifin MI, Chang SC, et al. Cellulose ether treatment in vivo generates chronic wasting disease prions with reduced protease resistance and delayed disease progression. J Neurochem. 2020. https://doi.org/10.1111/jnc.14877.CrossRefPubMed

34.

Nishizawa K, Teruya K, Oguma A, et al. Preparation and characterization of cellulose ether liposomes for the inhibition of prion formation in prion-infected cells. J Pharm Sci. 2019;108(8):2814–20. https://doi.org/10.1016/j.xphs.2019.03.025.CrossRefPubMed

35.

Ding M, Teruya K, Zhang W, et al. Decrease in skin prion-seeding activity of prion-infected mice treated with a compound against human and animal prions: a first possible biomarker for prion therapeutics. Mol Neurobiol. 2021;58(9):4280–92. https://doi.org/10.1007/s12035-021-02418-6.CrossRefPubMedPubMedCentral

36.

Teruya K, Oguma A, Arai K, et al. Polymorphisms in glia maturation factor β gene are markers of cellulose ether effectiveness in prion-infected mice. Biochem Biophys Res Commun. 2021;560:105–11. https://doi.org/10.1016/j.bbrc.2021.04.116.CrossRefPubMed

37.

Teruya K, Oguma A, Takahashi S, et al. Anti-prion activity of cellulose ether is impaired in mice lacking pre-T-cell antigen receptor α, T-cell receptor δ, or lytic granule function. Int Immunopharmacol. 2022;107:108672. https://doi.org/10.1016/j.intimp.2022.108672.CrossRefPubMed

38.

Zaheer A, Mathur SN, Lim R. Overexpression of glia maturation factor in astrocytes leads to immune activation of microglia through secretion of granulocyte-macrophage-colony stimulating factor. Biochem Biophys Res Commun. 2002;294(2):238–44. https://doi.org/10.1016/S0006-291X(02)00467-9.CrossRefPubMed

39.

Zaheer A, Zaheer S, Sahu SK, et al. A novel role of glia maturation factor: induction of granulocyte-macrophage colony-stimulating factor and pro-inflammatory cytokines. J Neurochem. 2007;101(2):364–76. https://doi.org/10.1111/j.1471-4159.2006.04385.x.CrossRefPubMed

40.

Stolmeier D, Thangavel R, Anantharam P, et al. Glia maturation factor expression in hippocampus of human Alzheimer’s disease. Neurochem Res. 2013;38(8):1580–9. https://doi.org/10.1007/s11064-013-1059-3.CrossRefPubMedPubMedCentral

41.

Kempuraj D, Thangavel R, Natteru PA, et al. Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine. 2016;1(1):1003.PubMedPubMedCentral

42.

Ahmed ME, Iyer S, Thangavel R, et al. Co-localization of glia maturation factor with NLRP3 inflammasome and autophagosome markers in human Alzheimer’s disease brain. J Alzheimer’s Dis. 2017;60(3):1143–60. https://doi.org/10.3233/JAD-170634.CrossRef

43.

Ahmed ME, Selvakumar GP, Kempuraj D, et al. Synergy in disruption of mitochondrial dynamics by Aβ (1–42) and glia maturation factor (GMF) in SH-SY5Y cells is mediated through alterations in fission and fusion proteins. Mol Neurobiol. 2019;56(10):6964–75. https://doi.org/10.1007/s12035-019-1544-z.CrossRefPubMedPubMedCentral

44.

Fan J, Fong T, Chen X, et al. Glia maturation factor-β: a potential therapeutic target in neurodegeneration and neuroinflammation. Neuropsychiatr Dis Treat. 2018;14:495–504. https://doi.org/10.2147/NDT.S157099.CrossRefPubMedPubMedCentral

45.

Thangavel R, Bhagavan SM, Ramaswamy SB, et al. Co-expression of glia maturation factor and apolipoprotein E4 in Alzheimer’s disease brain. J Alzheimer’s Dis. 2018;61(2):553–60. https://doi.org/10.3233/JAD-170777.CrossRef

46.

Thangavel R, Kempuraj D, Zaheer S, et al. Glia maturation factor and mitochondrial uncoupling proteins 2 and 4 expression in the temporal cortex of Alzheimer’s disease brain. Front Aging Neurosci. 2017;8(9):150. https://doi.org/10.3389/fnagi.2017.00150.CrossRef

47.

Selvakumar GP, Iyer SS, Kempuraj D, et al. Glia maturation factor dependent inhibition of mitochondrial PGC-1α triggers oxidative stress-mediated apoptosis in N27 rat dopaminergic neuronal cells. Mol Neurobiol. 2018;55(9):7132–52. https://doi.org/10.1007/s12035-018-0882-6.CrossRefPubMedPubMedCentral

48.

Selvakumar GP, Ahmed ME, et al. CRISPR/Cas9 editing of glia maturation factor regulates mitochondrial dynamics by attenuation of the NRF2/HO-1 dependent ferritin activation in glial cells. J Neuroimmune Pharmacol. 2019;14(4):537–50. https://doi.org/10.1007/s11481-019-09833-6.CrossRefPubMedPubMedCentral

49.

Selvakumar GP, Ahmed ME, Thangavel R, et al. A role for glia maturation factor dependent activation of mast cells and microglia in MPTP induced dopamine loss and behavioural deficits in mice. Brain Behav Immun. 2020;87:429–43. https://doi.org/10.1016/j.bbi.2020.01.013.CrossRefPubMedPubMedCentral

50.

Raikwar SP, Thangavel R, Dubova I, et al. Targeted gene editing of glia maturation factor in microglia: a novel Alzheimer’s disease therapeutic target. Mol Neurobiol. 2019;56(1):378–93. https://doi.org/10.1007/s12035-018-1068-y.CrossRefPubMed

51.

Ramaswamy SB, Bhagavan SM, Kaur H, et al. Glia maturation factor in the pathogenesis of Alzheimer’s disease. J Neurol Neurosurg. 2019;12(3):79–82.

52.

Bokvist M, Gröbner G. Misfolding of amyloidogenic proteins at membrane surfaces: the impact of macromolecular crowding. J Am Chem Soc. 2007;129(48):14848–9. https://doi.org/10.1021/ja076059o.CrossRefPubMed

53.

Aisenbrey C, Bechinger B, Gröbner G. Macromolecular crowding at membrane interfaces: adsorption and alignment of membrane peptides. J Mol Biol. 2008;375(2):376–85. https://doi.org/10.1016/j.jmb.2007.10.053.CrossRefPubMed

54.

Lee CF, Bird S, Shaw M, et al. Combined effects of agitation, macromolecular crowding, and interfaces on amyloidogenesis. J Biol Chem. 2012;287(45):38006–19. https://doi.org/10.1074/jbc.M112.400580.CrossRefPubMedPubMedCentral

55.

Ali T, Hannaoui S, Nemani S, et al. Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice. Acta Neuropathol Commun. 2021;9(1):58. https://doi.org/10.1186/s40478-021-01162-1.CrossRefPubMedPubMedCentral

56.

Tricine-SDS-PAGE SH. Nat Protoc. 2006;1(1):16–22. https://doi.org/10.1038/nprot.2006.4.CrossRef

57.

Ali T, Rehman SU, Khan A, et al. Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease. Mol Neurodegener. 2021;16(1):23. https://doi.org/10.1186/s13024-021-00445-4.CrossRefPubMedPubMedCentral

58.

Domert J, Rao SB, Agholme L, et al. Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol Dis. 2014;65:82–92. https://doi.org/10.1016/j.nbd.2013.12.019.CrossRefPubMed

59.

Sardar Sinha M, Ansell-Schultz A, Civitelli L, et al. Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. Acta Neuropathol. 2018;136(1):41–56. https://doi.org/10.1007/s00401-018-1868-1.CrossRefPubMedPubMedCentral

60.

Poduslo JF, Howell KG. Unique molecular signatures of Alzheimer’s disease amyloid β peptide mutations and deletion during aggregate/oligomer/fibril formation. J Neurosci Res. 2015;93(3):410–23. https://doi.org/10.1002/jnr.23507.8.CrossRefPubMed

61.

Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129–40. https://doi.org/10.1523/JNEUROSCI.1202-06.2006.CrossRefPubMedPubMedCentral

62.

Kempuraj D, Selvakumar GP, Thangavel R, et al. Mast cell activation in brain injury, stress, and post-traumatic stress disorder and Alzheimer’s disease pathogenesis. Front Neurosci. 2017;11:703.CrossRefPubMedPubMedCentral

63.

Kempuraj D, Ahmed ME, Selvakumar GP, et al. Brain injury-mediated neuroinflammatory response and Alzheimer’s disease. Neuroscientist. 2019. https://doi.org/10.1177/1073858419848293.CrossRefPubMedPubMedCentral

64.

Kempuraj D, Mentor S, Thangavel R, et al. Mast cells in stress, pain, blood-brain barrier, neuroinflammation and Alzheimer’s disease. Front Cell Neurosci. 2019;13:54.CrossRefPubMedPubMedCentral

65.

Thangavel R, Stolmeier D, Yang X, et al. Expression of glia maturation factor in neuropathological lesions of Alzheimer’s disease. Neuropathol Appl Neurobiol. 2012;38(6):572–81. https://doi.org/10.1111/j.1365-2990.2011.01232.x.CrossRefPubMedPubMedCentral

66.

Ennaceur A, Aggleton JP. Spontaneous recognition of object configurations in rats: effects of fornix lesions. Exp Brain Res. 1994;100(1):85–92. https://doi.org/10.1007/BF00227281.CrossRefPubMed

67.

Steckler T, Drinkenburg WH, Sahgal A, et al. Recognition memory in rats-I. Concepts and classification Prog Neurobiol. 1998;54(3):289–311. https://doi.org/10.1016/s0301-0082(97)00060-9.CrossRefPubMed

68.

Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res. 1988;31(1):47–59. https://doi.org/10.1016/0166-4328(88)90157-x.CrossRefPubMed

69.

Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process. 2012;13:93–110.CrossRefPubMed

70.

Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. https://doi.org/10.1038/nrd.2018.168.CrossRefPubMed

71.

Ihara M, Saito S. Drug repositioning for Alzheimer’s disease: finding hidden clues in old drugs. J Alzheimers Dis. 2020;74(4):1013–28. https://doi.org/10.3233/JAD-200049.CrossRefPubMed

72.

DeMattos RB, O’dell MA, Parsadanian M, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2002;99(16):10843–8. https://doi.org/10.1073/pnas.162228299.CrossRefPubMedPubMedCentral

73.

Murphy MP, LeVine H 3rd. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19(1):311–23. https://doi.org/10.3233/JAD-2010-1221.CrossRefPubMedPubMedCentral

74.

McAlpine FE, Lee JK, Harms AS, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009;34(1):163–77. https://doi.org/10.1016/j.nbd.2009.01.006.CrossRefPubMedPubMedCentral

75.

Van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: Pitfalls and promise. Biol Psychiatry. 2018;83(4):311–9. https://doi.org/10.1016/j.biopsych.2017.08.010.CrossRefPubMed

76.

Dhouafli Z, Cuanalo-Contreras K, Hayouni EA, et al. Inhibition of protein misfolding and aggregation by natural phenolic compounds. Cell Mol Life Sci. 2018;75(19):3521–38. https://doi.org/10.1007/s00018-018-2872-2.CrossRefPubMed

77.

Sharma V, Ghosh KS. Inhibition of amyloid fibrillation by small molecules and nanomaterials: strategic development of pharmaceuticals against amyloidosis. Protein Pept Lett. 2019;26(5):315–23. https://doi.org/10.2174/0929866526666190307164944.CrossRefPubMed

78.

Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2212948.CrossRefPubMed

79.

Da Mesquita S, Louveau A, Vaccari A, et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. Nature. 2018;560(7717):185–91. https://doi.org/10.1038/s41586-018-0368-8.CrossRefPubMedPubMedCentral

80.

Huang KL, Marcora E, Pimenova AA, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat Neurosci. 2017;20(8):1052–61. https://doi.org/10.1038/nn.4587.CrossRefPubMedPubMedCentral

81.

Zaheer A, Zaheer S, Thangavel R, et al. Glia maturation factor modulates beta-amyloid-induced glial activation, inflammatory cytokine/chemokine production and neuronal damage. Brain Res. 2008;1208:192–203. https://doi.org/10.1016/j.brainres.2008.02.093.CrossRefPubMedPubMedCentral

82.

Anand B, Wu Q, Nakhaei-Nejad M, Karthivashan G, et al. Significance of native PLGA nanoparticles in the treatment of Alzheimer’s disease pathology. Bioact Mater. 2022;17:506–25. https://doi.org/10.1016/j.bioactmat.2022.05.030.CrossRefPubMedPubMedCentral

Title: Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer’s disease
Authors: Tahir Ali
Antonia N. Klein
Keegan McDonald
Lovisa Johansson
Priyanka Ganguli Mukherjee
Martin Hallbeck
Katsumi Doh-ura
Hermann M. Schatzl
Sabine Gilch
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Alzheimer's Disease
Alzheimer's Disease
Published in: Journal of Neuroinflammation / Issue 1/2023
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-023-02858-y

2024 ASCO Annual Meeting

Springer Medicine

Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer’s disease

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Cortistatin deficiency reveals a dysfunctional brain endothelium with impaired gene pathways, exacerbated immune activation, and disrupted barrier integrity

Novel CH25H+ and OASL+ microglia subclusters play distinct roles in cerebral ischemic stroke

CD200 in dentate gyrus improves depressive-like behaviors of mice through enhancing hippocampal neurogenesis via alleviation of microglia hyperactivation

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study

Myeloid deficiency of the intrinsic clock protein BMAL1 accelerates cognitive aging by disrupting microglial synaptic pruning

Effects of diabetes on microglial physiology: a systematic review of in vitro, preclinical and clinical studies